Belite Bio, Inc. ADR (D01)
FSX
Delayed Data
Oct 26, 2026, 07:00 AM
Day's Range
127.0052 wk Range
76.50Overview - D01 - Belite Bio, Inc. ADR
Key Statistics
Valuation
Enterprise Value
5.44B
P/E (Trailing)
-60.60
PEG Ratio
-1.51
Price / Book
8.17
EV / EBITDA
-70.60
Profitability
Profit Margin
0.00%
Operating Margin
0.00%
Return on Assets
-15.65%
Return on Equity
-22.09%
Ownership
Shares Outstanding
40.27M
Float
19.55M
Held by Insiders
43.64%
Held by Institutions
24.26%
Price stats
Beta
-1.23
50-Day Avg
143.22
200-Day Avg
137.43
Market Cap - D01 - Belite Bio, Inc. ADR
Peers - D01 - Belite Bio, Inc. ADR
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- D01FSXBelite Bio, Inc. ADR5.79BMarket Cap+53.21%52-week change-60.61P/E (Trailing)0.00%Profit Margin
- ANLFSXAnalog Devices, Inc.166.10BMarket Cap+40.40%52-week change47.41P/E (Trailing)29.78%Profit Margin
- 0QFFSXModerna Inc.74.60BMarket Cap+88.69%52-week change25.27P/E (Trailing)-141.42%Profit Margin
- 1AEFSXargenx SE48.77BMarket Cap+8.36%52-week change31.83P/E (Trailing)31.73%Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt45.90BMarket Cap-5.00%52-week change32.46P/E (Trailing)32.26%Profit Margin
- 64BFSXAstera Labs, Inc.40.42BMarket Cap+41.34%52-week change133.91P/E (Trailing)30.74%Profit Margin
- 49BAFSXBeOne Medicines Ltd. American Depositary Shares37.54BMarket Cap+19.39%52-week change69.73P/E (Trailing)10.69%Profit Margin
Profile Summary - D01 - Belite Bio, Inc. ADR
About
Belite Bio, Inc. ADR is a clinical-stage biopharmaceutical company focused on developing oral therapies for degenerative retinal diseases and selected metabolic disorders. Its lead candidate, Tinlarebant, is being studied for eye conditions such as Stargardt disease type 1 and geographic atrophy, with an emphasis on…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
